NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Weiss, Brian D., Wolters, Pamela L., Plotkin, Scott R., Widemann, Brigitte C., Tonsgard, James H., Blakeley, Jaishri, Allen, Jeffrey C., Schorry, Elizabeth, Korf, Bruce, Robison, Nathan J., Goldman, Stewart, Vinks, Alexander A., Emoto, Chie, Fukuda, Tsuyoshi, Robinson, Coretta T., Cutter, Gary, Edwards, Lloyd, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2021
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078274/
https://ncbi.nlm.nih.gov/pubmed/33507822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02220
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky